Likelihood of Approval and Phase Transition Success Rate Model – Canakinumab in Anemia
Powered by
Unlock hidden opportunities in the LoA industry
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model – Canakinumab in Anemia report and make more profitable business decisions.
This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.
Canakinumab in Anemia Drug Details:
Canakinumab (Ilaris / Lasprona / Vyncro) is a fully human monoclonal antibody. It is formulated as powder for solution and solution for subcutaneous route of administration. Ilaris is indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and children 4 years of age and older including Familial Cold Autoinflammatory Syndrome (FCAS), tumour necrosis factor (TNF) receptor associated periodic syndrome (TRAPS), hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD), Familial Mediterranean Fever (FMF), Muckle-Wells Syndrome (MWS), pancreatic cancer and symptomatic anemia. Ilaris is also approved for systemic onset juvenile idiopathic arthritis in patients aged 2 years and older. Ilaris is also indicated for the symptomatic treatment of adult patients with frequent gouty arthritis attacks, and for the treatment of Active Still’s disease, including Adult-Onset Still’s Disease (AOSD). Canakinumab is indicated for emergency use in the treatment of COVID-19.Canakinumab (Ilaris) is under development for the treatment of myelodysplastic syndromes, mild cognitive impairment due to Alzheimer’s disease, adult onset still’s disease (AOSD), renal cell carcinoma, metastatic non-squamous (adjuvant and first line therapy), metastatic triple negative breast cancer, pulmonary sarcoidosis, metastatic melanoma, alcoholic hepatitis, pyogenic sterile arthritis pyoderma gangrenosum and acne (PAPA) syndrome and pain associated with sickle cell anemia patients. It was under development for the treatment of arterial structure, function in intermittent claudication patients, gouty arthritis (in the US), abdominal aortic aneurysms, choroidal neovascularization, rheumatoid arthritis, type 1 diabetes, type 2 diabetes, chronic obstructive pulmonary disease (COPD), feratoconjunctivitis sicca (dry eye), secondary prevention of cardiovascular events, Kawasaki disease, urticaria vasculitis, polymyalgia rheumatica, non-small cell lung cancer (second line and third line therapy) and knee osteoarthritis. It is also administered through intraarticular route. It was also under development for the treatment of COVID-19-induced pneumonia, cytokine release syndrome and squamous non-small cell lung cancer (first line therapy), Behcet disease.
Report Coverage
The data is segmented by drug name per indication and shows the current likelihood of approval for the drug compared to the indication benchmark and the industry benchmark.
The Likelihood of Approval data is updated regularly based on events that take place which impact the clinical development process and regulatory considerations. GlobalData’s proprietary machine learning models consider these events in real time, to produce quantitative changes to the LOA and PTSR along with qualitative reasoning why the likelihood of approval has changed.
Quick View – Canakinumab LOA Data | |||||
Report Segments |
|
||||
Drug Name |
|
||||
Administration Pathway |
|
||||
Therapeutic Areas |
|
||||
Key Manufacturers |
|
||||
Drug Development Status |
|
Reasons to Buy
- Precise Likelihood of Approval and Phase Transition Success Rates: Our machine learning and proprietary models provide accurate predictions, helping you gauge the potential success of a drug in the regulatory process.
- Competitive Strategy Planning: Access information on LOA and PTSR for competitors’ drugs, allowing you to plan your clinical development, commercialisation and marketing strategies
- Event-driven Updates: Track event-driven changes in LOA and PTSR benchmarked against indication LOA/PTSR. Get the latest insights to adapt your strategies promptly!
- Well-informed Investment Decisions: This data helps you navigate the dynamic landscape of drug development and regulatory considerations.
Scope
- Drug Details: Drug name, Drug type, Intervention type
- Administration Pathway
- Therapeutic Areas
- Key Manufacturers
- Drug Development Status
This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance.
Frequently asked questions
- Drugs which have been approved in the past 10 years
- Drugs which have failed during clinical development in the past 18 years
- Drugs which are currently in development
- Phase I, Phase II, Phase III, and Pre-Registration development stage
- Drugs must meet one of the following criteria to be included in the model:
- The developer has specified the US as an intended market for approval.
- The developer has not specified any country as an intended market for approval, i.e. the “Drug Geography” is listed as “Global”
- Innovator drugs and biosimilars
- Diagnostics, Imaging Agents, Biomarkers, stents and other drug delivery devices (covered in GlobalData’s Medical Intelligence Center).
- Nutraceuticals, dietary supplements, alternative medicines, imaging agents, radio emitter, transplants, transfusions, fillers, cosmetics, probiotics, antiseptics, antacids, mobilizing agents, veterinary drugs and drugs not seeking approval.
- Generic drugs
- Innovative drugs in Preclinical or Discovery Stage.
- Pipeline drugs sponsored by a Government or Institution.
- Drugs with a specific Drug Geography not the United States.
The probability of a drug ultimately receiving market authorization
The probability of a drug’s advancement to the next stage of clinical development
GlobalData’s Drug-Specific Likelihood of Approval (LoA) calculates the Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA) customized to individual drug. The model uses a combination of Machine Learning (ML) and a GlobalData proprietary algorithm to process data points from the Drugs, Clinical Trials, Regulatory Milestones, Company, and Financial databases.
Inclusion
Data Scope:
Drug Phase Scope:
Drug Geography Scope:
Drug Type Scope:
Entity Type Scope:
Only drugs in development by companies are included in the model.
Exclusion
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745